About Blue Knight
BLUE KNIGHT™ is a joint initiative between Johnson & Johnson Innovation – JLABS (JLABS) and the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services. This collaboration aims to stimulate the innovation and incubation of science and technologies that may improve health security and response by supporting companies focused on public health threats and emerging infectious diseases.
Learn more and explore the portfolio companies: https://jnjinnovation.com/jlabs/blue-knight
JLABS and BARDA are hosting the third Blue Knight Symposium in Boston, MA on June 4, 2023. Held in association with the 2023 BIO International Convention, you can now register for the chance to dive into a global conversation on advancing next-gen potential preparedness solutions. Attendance is limited and in-person only. Register: https://2023blueknightsymposium.splashthat.com/
About HHS, ASPR and BARDA
HHS works to enhance and protect the health and well-being of all Americans, providing for effective health and human services and fostering advances in medicine, public health, and social services. The mission of ASPR is to assist the country in preparing for, responding to, and recovering from public health emergencies and disasters. Within ASPR, BARDA invests in the innovation, advanced research and development, acquisition, and manufacturing of medical countermeasures – vaccines, drugs, therapeutics, diagnostic tools, and non-pharmaceutical products – needed to combat health security threats. To date, BARDA-supported products have achieved over 70 FDA approvals, licensures or clearances. To learn more about BARDA’s portfolio and about partnering with BARDA, visit www.medicalcountermeasures.gov/.
BLUE KNIGHT™ is a joint initiative between Johnson & Johnson Innovation – JLABS (JLABS) and the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services. This collaboration aims to stimulate the innovation and incubation of science and technologies that may improve health security and response by supporting companies focused on public health threats and emerging infectious diseases.
Learn more and explore the portfolio companies: https://jnjinnovation.com/jlabs/blue-knight
JLABS and BARDA are hosting the third Blue Knight Symposium in Boston, MA on June 4, 2023. Held in association with the 2023 BIO International Convention, you can now register for the chance to dive into a global conversation on advancing next-gen potential preparedness solutions. Attendance is limited and in-person only. Register: https://2023blueknightsymposium.splashthat.com/
About HHS, ASPR and BARDA
HHS works to enhance and protect the health and well-being of all Americans, providing for effective health and human services and fostering advances in medicine, public health, and social services. The mission of ASPR is to assist the country in preparing for, responding to, and recovering from public health emergencies and disasters. Within ASPR, BARDA invests in the innovation, advanced research and development, acquisition, and manufacturing of medical countermeasures – vaccines, drugs, therapeutics, diagnostic tools, and non-pharmaceutical products – needed to combat health security threats. To date, BARDA-supported products have achieved over 70 FDA approvals, licensures or clearances. To learn more about BARDA’s portfolio and about partnering with BARDA, visit www.medicalcountermeasures.gov/.
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
